Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
June 18th, 2020
23.7K views
Here, we present a protocol for measurement of hepatic venous pressure gradient (HVPG),the gold standard to diagnose clinically significant portal hypertension. Moreover, we describe how to perform a transjugular liver biopsy within the same session.
Overview
This article presents a protocol for measuring the hepatic venous pressure gradient (HVPG), which is the gold standard for diagnosing clinically significant portal hypertension. Additionally, it describes the procedure for performing a transjugular liver biopsy within the same session.
Key Study Components
Area of Science
- Neuroscience
- Hepatology
- Clinical Medicine
Background
- Portal hypertension is a significant complication of advanced chronic liver disease.
- HVPG measurement is crucial for assessing disease severity and treatment response.
- Understanding HVPG can guide individualized treatment approaches.
- It provides insights into the pathophysiological mechanisms of cirrhosis.
Purpose of Study
- To establish a reliable protocol for HVPG measurement.
- To enhance diagnostic accuracy for portal hypertension.
- To integrate transjugular liver biopsy into the HVPG measurement session.
Methods Used
- Measurement of HVPG using a balloon catheter.
- Flushing the catheter with contrast medium before use.
- Inflating and deflating the balloon to ensure instrument integrity.
- Performing a transjugular liver biopsy concurrently.
Main Results
- HVPG measurement is validated as the gold standard for diagnosing portal hypertension.
- Clinical benefits of HVPG reduction are established across various liver disease etiologies.
- The protocol allows for efficient diagnosis and treatment planning.
- Insights gained from HVPG measurement can influence patient management.
Conclusions
- HVPG is essential for diagnosing portal hypertension in chronic liver disease.
- The integrated approach improves patient care and diagnostic efficiency.
- Future studies may further elucidate the role of HVPG in clinical practice.
Frequently Asked Questions
What is HVPG?
HVPG stands for hepatic venous pressure gradient, a key measure in diagnosing portal hypertension.
Why is HVPG important?
It provides critical insights into the severity of portal hypertension and guides treatment decisions.
How is HVPG measured?
HVPG is measured using a balloon catheter inserted into the hepatic vein.
What is a transjugular liver biopsy?
It is a procedure to obtain liver tissue for diagnosis, performed through the jugular vein.
Can HVPG measurement and liver biopsy be done together?
Yes, this article describes a protocol for performing both procedures in the same session.
What are the clinical implications of HVPG?
HVPG measurement helps in assessing treatment response and tailoring patient management.
Executive Industry Relevance
Hepatic venous pressure gradient (HVPG) measurement provides a quantitative, clinically validated biomarker for assessing portal hypertension severity in advanced chronic liver disease. This hemodynamic parameter enables mechanistic de-risking in preclinical and translational research by correlating portal pressure with fibrotic progression and treatment response. Integration of transjugular liver biopsy within the same procedure supports histopathological validation, enhancing target confidence in antifibrotic and anti-portal hypertensive drug development pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses related to portal hemodynamics and fibrotic pathway modulation in disease-relevant models.
- Operational Value: Provides a gold-standard physiological readout for validating target engagement in preclinical studies of portal hypertension.
Screening & Assay Development
- Scientific Value: Generates quantitative, reproducible hemodynamic measurements (WHVP, FHVP, HVPG) suitable for assay standardization and inter-laboratory comparability.
- Operational Value: Supports development of surrogate biomarkers and pharmacodynamic readouts for high-throughput screening of compounds targeting sinusoidal resistance or splanchnic vasodilation.
Translational & Preclinical Research
- Scientific Value: Facilitates translational continuity by aligning animal model phenotypes with human HVPG thresholds (e.g., ≥10 mm Hg for clinically significant portal hypertension).
- Operational Value: Enables longitudinal monitoring of disease progression and treatment response in preclinical models using minimally invasive, repeatable hemodynamic sampling.
Pipeline & Workflow Integration
The HVPG measurement protocol fits within the discovery-to-preclinical continuum, particularly in vascular biology and fibrosis-focused programs where hemodynamic endpoints inform go/no-go decisions.
- Discovery Biology: Supports mechanistic de-risking by quantifying the impact of genetic or pharmacological interventions on portal venous pressure and hepatic hemodynamics.
- Screening: Delivers standardized, quantitative pressure gradients that enable dose-response characterization and compound ranking in antifibrotic campaigns.
- Analytics: Provides continuous, triplicate-recorded hemodynamic data with clear decision thresholds (HVPG ≥10 mm Hg) for statistical analysis and biomarker qualification.
- Translational Research: Bridges preclinical findings to clinical relevance through direct alignment with human HVPG diagnostic criteria and biopsy-confirmed fibrosis staging.
- Enterprise Reuse: Establishes a reusable hemodynamic platform for multi-indication liver fibrosis and portal hypertension programs across therapeutic areas.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by linking molecular targets to functional hemodynamic outcomes in liver pathophysiology.
- Operational Value: Ensures procedural standardization through fluoroscopic guidance, contrast validation, and triplicate pressure recording requirements.
- Strategic Value: Improves capital efficiency by enabling early identification of non-responders via HVPG non-response, reducing late-stage failure risk.
- Portfolio Impact: Informs risk-adjusted prioritization of drug candidates based on HVPG reduction efficacy and histopathological correlation from transjugular biopsy.
Implementation Considerations
- Requires expertise in interventional radiology or hepatology for vascular access and catheter manipulation.
- Dependent on fluoroscopy, pressure transduction systems, and contrast-compatible catheter introducer sheaths.
- Necessitates standardization of wedge position validation via contrast injection and occlusion confirmation to ensure measurement reliability.
- Adaptation across model systems requires anatomical scaling of hepatic vein catheterization techniques and pressure transducer calibration.
- Practical limitations include procedural duration (30–45 min), need for patient breath-holding during biopsy, and reliance on operator proficiency to minimize complications.
Biopharma FAQs
Why does HVPG measurement matter for target validation?
HVPG measurement provides a quantitative, gold-standard biomarker for portal hypertension severity, enabling mechanistic de-risking by linking target modulation to hemodynamic outcomes in preclinical models. Changes in HVPG reflect alterations in sinusoidal resistance and portal blood flow, offering direct insight into pathophysiological mechanisms driving fibrosis progression. This supports target confidence by validating functional relevance beyond molecular engagement.
How does isolating the hepatic venous pressure variable support discovery pipeline decisions?
Isolating wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) allows precise calculation of HVPG, eliminating confounding systemic venous pressures. This isolation enables accurate assessment of intrahepatic resistance, a key determinant in portal hypertension pathogenesis. By controlling for right atrial and IVC pressures, researchers obtain a disease-specific hemodynamic readout suitable for target validation and compound screening.
What do quantitative HVPG measurements enable in antifibrotic screening campaigns?
Quantitative HVPG measurements (WHVP, FHVP, and their difference) provide continuous, triplicate-recorded data with a validated clinical threshold (≥10 mm Hg) for clinically significant portal hypertension. These outputs support dose-response modeling, IC50 estimation, and biomarker qualification in screening cascades. The reproducibility of the method enables cross-study comparison and go/no-go decisions based on hemodynamic efficacy.
Why are replication requirements (triplicate recordings) important for cross-functional collaboration?
Triplicate recordings of WHVP and FHVP ensure measurement reliability and reduce variability from respiratory or cardiac fluctuations, enhancing data robustness. This standardization allows consistent interpretation across discovery, preclinical, and clinical teams using the same hemodynamic endpoint. Reproducible HVPG values facilitate alignment between pharmacodynamic biomarkers and clinical endpoints in translational research.
What statistical analysis capabilities are required before implementing HVPG measurement in a discovery workflow?
Implementation requires capability to record, average, and statistically analyze triplicate pressure waveforms to derive mean HVPG values with confidence intervals. Teams must be able to apply threshold-based analysis (e.g., HVPG ≥10 mm Hg) for responder/non-responder stratification. Additionally, correlation analysis with histopathological scores from transjugular biopsy enables biomarker qualification and translational validity assessment.
Chapters in this video
0:05
Introduction
1:04
Hepatic Vein Balloon Catheter Placement
2:59
Hepatic Venous Pressure Gradient (HVPG) Hemodynamic Reading Assessment
3:53
Transjugular Core Liver Biopsy
5:32
Results: Representative Pressure Tracing of Free and Wedged Hepatic Pressure Readings
6:14
Conclusion
